Vivos Therapeutics VVOS 深 沪
等待开盘 11-06 09:30:00 美东时间
2.4323
+0.072
+3.06%
华盛通- 最 高2.4348
- 今 开2.36
- 成交量 1.45万股
- 最 低 2.36
- 昨 收 2.36
- 总市值 1825.39万
- 52周最高 7.95
- 市盈率 静 --
- 换手率 0.19%
- 52周最低 1.98
- 委 比 -56.25%
- 总股本 750.48万
- 历史最高 360.25
- 量 比 0.38
- 振 幅 3.17%
- 历史最低 1.91
- 每 手 1
- 风险率 1.03%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Vivos' Study Demonstrates Its Daytime-Nighttime Appliance Provides Relief, Quality Of Life Improvement In Children With Attention-Deficit/Hyperactivity Disorder, Obstructive Sleep Apnea
Previously Unpublished Data Confirms Vivos DNA Devices Offer a Safe and Effective Alternative Treatment for Children with ADHD and Obstructive Sleep Apnea LITTLETON, Colo., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Vivos
09-30 20:41
Vivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device
Vivos Therapeutics发布新数据显示，其FDA认证的DNA设备能有效缓解儿童ADHD和阻塞性睡眠呼吸暂停（OSA）症状。该设备是非手术、非药物治疗中重度OSA的创新方案，临床试验显示患儿症状改善显著。
09-30 12:30
Vivos Therapeutics Announces Peer-Reviewed Published Data Confirming That Vivos DNA Is Both Safe And Efficacious In Treating Children Suffering From OSA
Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for
09-17 20:34
Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment
Vivos Therapeutics' Vivos DNA appliance, part of the C.A.R.E. line, has been proven safe and effective in treating children with obstructive sleep apnea (OSA) in a multicenter clinical trial published in *The European Journal of Pediatrics*. The study showed that 77% of participants experienced at least a 50% reduction in OSA severity, and 93% of severe cases achieved this reduction. The appliance increases airway volume by 67.8% and reduces slee...
09-17 12:30
美股大行评级 | 潜在涨幅577.08%！Veritone获D. Boral Capital升目标价至26美元，维持"买入"评级
今日重点评级关注：D. Boral Capital：维持Veritone"买入"评级，目标价从6美元升至26美元；Guggenheim：维持Dianthus Therapeutics"买入"评级，目标价从92美元升至100美元
09-10 18:01
Ascendiant Capital Maintains Buy on Vivos Therapeutics, Raises Price Target to $6.5
Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and raises the price target from $6.2 to $6.5.
09-09 19:18
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers OSR Holdings (NASDAQ:OSRH) shares rose 34.6% to $0.7 during Friday's a...
08-23 05:07
Vivos Therapeutics Q2 EPS $(0.55) Misses $(0.35) Estimate, Sales $3.820M Beat $3.783M Estimate
Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.35) by 57.14 percent. This is a 8.33 percent increase over losses of $(0.60) per share
08-20 04:23
Vivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference Call
Vivos Therapeutics, Inc. will release its Q2 2025 financial results after market close on August 19, 2025, followed by a conference call at 5:00 pm ET to discuss results and recent developments. The call can be accessed by dialing (800) 717-1738 (US) or (646) 307-1865 (int'l), with a replay available until September 2, 2025. A live webcast and archive will be available on Vivos' website. The company focuses on treating sleep-related breathing dis...
08-19 12:30
